1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec

An R&D overhaul trimmed 17 candidates from the pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.

In the 18 months since George Scangos arrived from Exelixis Inc. to take the chief executive’s spot at Biogen Inc., the big biotech has overhauled its R&D apparatus, cutting two major therapeutic areas while tightening focus around another three areas. As the company provided an R&D update during an analyst day presentation June 12, it remained clear, though, that while much has changed at Biogen, near-term growth prospects center on BG-12 in multiple sclerosis and a pair of long-acting coagulation factors in hemophilia.

Shortly after taking control, Scangos brought in former ZymoGenetics Inc. CEO Douglas Williams as executive VP, R&D Also see...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey

 
• By Vibha Sharma

The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 
• By Anabel Costa-Ferreira

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 
• By Anabel Costa-Ferreira

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

Research Advances And Filings Prompt EMA To Revise Alzheimer’s Trial Guideline

 
• By Neena Brizmohun

Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.

More from R&D